OP20: Postoperative endoscopic recurrence after resection of Crohn’s terminal ileitis with Kono-S or side-to-side functional end anastomosis: results of a Multicenter Prospective Randomized TrialECCO'24Year: 2024
Authors: Trencheva, K.(1)*;Spinelli, A.(2);Kienle, P.(3);D@E@Hoore, A.(4);Luglio, G.(5);Flemming, S.(6);Scaringi, S.(7);Tropeano, F.(5);Christos, P.(8);Michelassi , F.(1);
(1)Weill Cornell Medicine, Department of Surgery, New York, United States;(2)Humanitas Rozzano Milano- Humanitas University, Colon and Rectal Surgery, Milan, Italy;(3)Theresienhospital and St. Hedwig-Clinic gGmbH, Department of General and Abdominal Surgery, Mannheim, Germany;(4)University Hospitals Leuven, Department of Abdominal surgery, Leuven, Belgium;(5)University of Naples Federico II, Department of Public Health, Naples, Italy;(6)University Hospital Würzburg, Department of Surgery, Würzburg, Germany;(7)Careggi University Hospital, Department of Surgery and Translational Medicine, Florence, Italy;(8)Weill Cornell Medicine, Population Health Sciences, New York, United States;
OP21: Spatial Transcriptomics of Pre-treatment Biopsies Revealing Molecular Maturation State and Chronic Crypt Damage, Reflecting Histological Severity, as Predictors of Primary Responsiveness to TNF-α Inhibitors in Bio-naive Ulcerative Colitis PatientsECCO'24Year: 2024
Authors: Kim, S.W.(1)*;Na, K.(1);Oh, S.J.(2);Lee, C.K.(2);
(1)Kyung Hee University Hospital- Kyung Hee University College of Medicine, Pathology, Seoul, Korea- Republic Of;(2)Kyung Hee University Hospital- Kyung Hee University College of Medicine, Gastroenterology, Seoul, Korea- Republic Of;
OP22: Topical Sphingosine-1-Phosphate (S1P) Receptor 1 Modulation Regulates Gut Angiogenesis in Inflammatory Bowel DiseasesECCO'24Year: 2024
Authors: Wang, J.(1);West, G.(2);Lin, S.(3);Mukherjee, P.(2);Maddux, R.(4);Wu, C.(4);Hu, S.(4);Nguyen, Q.T.(2);Czarnecki, D.(2);Le, H.N.(2);Mao, R.(2);Chandra, J.(2);Hu, S.(5);Gordon, I.(5);Petersen, A.(4);Harris, S.(4);Rieder, F.(2,6)*;
(1)Xinxiang Medical University, Henan Key Laboratory of Immunology and Targeted Drug, Xinxiang, China;(2)Cleveland Clinic, Inflammation and Immunity, Cleveland, United States;(3)The First Affiliated Hospital of Sun Yat-sen University, Department of Gastroenterology and Hepatology, Guangzhou, China;(4)Bristol Myers Squibb, Translational Medicine, Princeton, United States;(5)Cleveland Clinic, Anatomic Pathology, Cleveland, United States;(6)Cleveland Clinic, Gastroenterology- Hepatology and Nutrition, Cleveland, United States;
OP23: Guselkumab induction restores intestinal immune homeostasis and promotes epithelial repair in moderately to severely active Ulcerative ColitisECCO'24Year: 2024
Authors: Sridhar, S.(1);Hart, A.(1);Venkat, S.(1);Ruane, D.(2);Horowitz, D.(1);Lee, T.(1);Waterworth, D.(1);Huang, K.H.G.(1);Germinaro, M.(1);Vetter, M.(1);Cua, D.(1);Freeman, T.C.(1);Sisk, C.(1);McRae, B.(3);Verstockt, B.(4)*;Rubin, D.T.(5);Sands, B.E.(6);Branigan, P.(1);
(1)Janssen Research & Development LLC, Research & Development, Spring House, United States;(2)Janssen Research & Development LLC, Research & Development, La Jolla, United States;(3)Janssen Research & Development LLC, Research & Development, Cambridge, United States;(4)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(5)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(6)Icahn School of Medicine at Mount Sinai, The Henry D. Janowitz Division of Gastroenterology, New York, United States;
OP24: SPP1 in colitis-associated colon cancerECCO'24Year: 2024
Authors: Manna, S.(1)*;Cardoso da Silva, D.(1);Sehn, M.(2);Weise, J.(1);Heldt, C.(1);Plumbom, I.(3);Conrad, T.(3);Schallenberg, S.(4);Dony, V.(1);Farahani, S.K.(5);Weiss, F.(5);Branchi, F.(1);Elezkurtaj, S.(4);Siegmund, B.(1);Weixler, B.(2);Hummel, M.(4);Gröne, J.(2);Schumann, M.(1);
(1)Charité Universitätsmedizin Berlin, Department for Gastroenterology- Rheumatology and Infectious Diseases, Berlin, Germany;(2)Charité Universitätsmedizin Berlin, Department of Visceral Surgery, Berlin, Germany;(3)Max-Delbrueck-Center for Molecular Medicine, BIH/MDC Genomics Platform, Berlin, Germany;(4)Charité Universitätsmedizin Berlin, Institute of Pathology and Molecular Pathology, Berlin, Germany;(5)Charité Universitätsmedizin Berlin, Institute for Clinical Physiology, Berlin, Germany;
OP25: Dual activation of GCGR/GLP1R signaling ameliorates intestinal fibrosis via metabolic regulation of histone H3K9 lactylation in epithelial cellsECCO'24Year: 2024
Authors: Liu, H.(1)*;Hong, Y.(1);Wang, X.(1);Dong, J.(1);Li, X.(1);Shi, Z.(1);Wang, J.(2);Zhou, L.(3);Rieder, F.(4);Chen, B.(3);Chen, M.(3);Zhang, Y.(2);Mao, R.(3);Jiang, X.(1);
(1)Sun Yat-Sen University, School of Pharmaceutical Sciences, Guangzhou, China;(2)Ruijin Hospital, Department of Gastroenterology, Shanghai, China;(3)The First Affiliated Hospital of Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China;(4)Cleveland Clinic Foundation, Department of Gastroenterology, Cleveland, United States;
OP26: Programmable probiotic local delivery of anti-TNF-α nanobody to alleviate DSS-induced colitisECCO'24Year: 2024
Authors: Kang, G.(1)*;Zhu, Z.(1);Gao, M.(1);Wang, L.(1);Cao, X.(2);Liu, X.(3);Huang, H.(1);
(1)Tianjin University, Department of Biochemical Engineering, Tianjin, China;(2)Tianjin Medical University General Hospital, Department of Gastroenterology and Hepatology, Tianjin, China;(3)Beijing Chaoyang Hospital, Department of Gastroenterology and Hepatology, Beijing, China;
OP27: Oxalyl-CoA decarboxylase is a major and specific virulence factor for Adherent Invasive Escherichia coliECCO'24Year: 2024
Authors: Toumi, E.(1)*;Orianne, G.(2);Reisacher, C.(1);Rolhion, N.(3);Sokol , H.(2,3);Skurnik, D.(1,4);
(1)CNRS- INSERM- Institut Necker Enfants Malades-INEM, Department of Immunology- Infectiology and Hematology, Paris, France;(2)Micalis Institute- INRAE- AgroParisTech- Jouy en Josas, Commensal and Probiotics Host Interactions ProbiHote, Jouy en Josas, France;(3)Saint Antoine Hospital- Centre de recherche Saint Antoine- CRSA- INSERM, Gastroenterology Department, Paris, France;(4)Hôpital Necker-Enfants Malades, Département de Microbiologie, Paris, France;
OP28: Defective STAT3 signaling in refractory Very Early Onset Inflammatory Bowel Disease is associated with a transcriptional signature which predicts response to anti-IL23-based therapiesECCO'24Year: 2024
Authors: Collen, L.(1)*;Beckmann, N.(2);Mitsialis, V.(3);Eran, A.(1);Field, M.(4);Kim, D.(4);Bao, B.(4);Barends, J.(4);Saccocia, G.(4);Bresnahan, M.(4);Yang, J.(4);Combs, A.(4);Tuthill, M.(4);Bearup, R.(4);Okoroafor, I.(4);Patik, I.(4);Grushkin-Lerner, L.(4);Ouahed, J.(1);Muise, A.(5);Klein, C.(6);Horwitz, B.(1);Schadt, E.(7);Argmann, C.(7);Snapper, S.(1);
(1)Boston Children@E@s Hospital and Harvard Medical School, Division of Gastroenterology, Boston- MA, United States;(2)Icahn School of Medicine at Mt Sinai, Division of Data Driven & Digital Medicine, New York- NY, United States;(3)Brigham and Women@E@s Hospital, Division of Gastroenterology, Boston- MA, United States;(4)Boston Children@E@s Hospital, Division of Gastroenterology, Boston- MA, United States;(5)Sick Kids Toronto, Division of Gastroenterology, Toronto, Canada;(6)Dr. von Hauner Childrens Hospital, Department of Pediatric Hematology/Oncology, Munich, Germany;(7)Icahn School of Medicine at Mt Sinai, Genetics and Genomic Sciences, New York- NY, United States;
OP29: Haematopoietic stem cell gene therapy as a treatment for severe Crohn’s Disease associated with pathogenic NOD2 genetic variantsECCO'24Year: 2024
Authors: Enjalbert, F.(1);del Mar Masdeu, M.(1);Zabinski , T.(1);Narean, J.S.(1);Elavazhagan, S.(1);Whiting , C.(1);Pennucci, V.(1);Luiz , A.(1);Du, L.(1);Recchi, C.(1);Cattoni, M.(1);Heal , P.(1);Gaspar , B.(1);Mavilio , F.(1);Sagoo, P.(1)*;
(1)Orchard Therapeutics Ltd., Translational Research, London, United Kingdom;
OP30: Endothelial cell-mediated smooth muscle hyperplasia in Crohn’s disease intestinal strictures: Caveolin 1 as a potential therapeutic targetECCO'24Year: 2024
Authors: Acharjee, A.(1,2);Shivaji, U.N.(3,4);Santacroce, G.(5)*;Jeffery, L.(4);Amamou, A.(5);Reynolds, G.(6);Majumder, S.(4,5);Akiror, S.(6);Zardo, D.(7);Gkoutos, G.V.(1,2);Ghosh, S.(5);Iacucci, M.(3,4,5);
(1)Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom;(2)Centre for Health Data Research, University of Birmingham, Birmingham, United Kingdom;(3)Gastroenterology- Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom;(4)Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom;(5)APC Microbiome Ireland- College of Medicine and Health, University College of Cork, Cork, Ireland;(6)Centre for Liver and Gastrointestinal Research, University of Birmingham, Birmingham, United Kingdom;(7)Department of Pathology, San Bortolo Hospital, Vicenza, Italy;
OP31: Single-cell analyses identify immune and stromal signatures of perianal fistulizing Crohn@E@s DiseaseECCO'24Year: 2024
Authors: Cao, S.(1)*;Nguyen, K.(2);Colonna, M.(2);Deepak, P.(3);
(1)Washington University in St. Louis, Gastroenterology, St. Louis, United States;(2)Washington University, Pathology and Immunology, St. Louis, United States;(3)Washington University, Gastroenterology, St. Louis, United States;
OP32: TWIST1-mediated fibroblast activation protein (FAP)-expressing fibroblasts drives fibrosis in Crohn’s DiseaseECCO'24Year: 2024
Authors: Ke, B.J.(1)*;Abdurahiman, S.(1);Verstockt, B.(1);Biscu, F.(1);Zanella, G.(1);Zouzaf, A.(1);van Baarle, L.(1);De Simone, V.(1);Stakenborg, M.(1);Santhosh, S.(1);Verstockt, S.(1);De Hertogh, G.(2);Vermeire, S.(1);Matteoli, G.(1);
(1)KU Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;(2)University Hospitals Leuven, Department of Pathology, Leuven, Belgium;
OP34: Risk of Disease Recurrence and Re-resections in Crohn@E@s Disease Patients Undergoing Primary Bowel Resection: A Population-Based StudyECCO'24Year: 2024
Authors: Poulsen, A.(1)*;Rasmussen, J.(2);Wewer, M.D.(3);Hansen, E.H.(4);Nordestgaard, R.L.M.(3);Jespersen, H.S.R.(3);Christiansen, D.(2);Lin, V.A.(5);Surnacheva, E.(1);Aydemir, N.(2);Verlo, K.A.(3);Pachler, F.R.(6);Ovesen, P.D.(6);Fuglsang, K.A.(7);Brandt, C.F.(7); Sørensen, L.T.(1);Gögenur, I.(5);Krarup, P.M.(1); Burisch, J.(3);Seidelin, J.B.(6);
(1)Copenhagen University Hospital- Bispebjerg, Digestive Disease Center, Copenhagen NV, Denmark;(2)Zealand University Hospital, Department of Medical Gastroenterology, Koege, Denmark;(3)Copenhagen University Hospital - Amager and Hvidovre, Gastrounit- Medical Section, Hvidovre, Denmark;(4)North Zealand University Hospital, Department of Gastroenterology, Frederikssund, Denmark;(5)Zealand University Hospital, Center for Surgical Science, Koege, Denmark;(6)Copenhagen University Hospital- Herlev and Gentofte, Department of Gastroenterology and Hepatology, Herlev, Denmark;(7)University Hospital of Copenhagen- Rigshospitalet, Department of Medical Gastroenterology, Copenhagen, Denmark;
OP35: Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn’s disease: Results from the phase 3 VIVID 1 studyECCO'24Year: 2024
Authors: Jairath, V.(1,2)*;Sands, B.E.(3);Bossuyt, P.(4);Farraye, F.(5);Ferrante, M.(6);Hisamatsu, T.(7);Kaser, A.(8);Kierkus, J.(9);Laharie, D.(10);Reinisch, W.(11);Siegmund, B.(12);Bragg, S.M.(13);Hon, E.(14);Lin, Z.(13);Ugolini Lopes, M.(13);Morris, N.(13);Protic, M.(13);Danese, S.(15,16);
(1)University Hospital, Division of Gastroenterology- Department of Medicine, London- ON, Canada;(2)Western University, Division of Epidemiology and Biostatistics, London- ON, Canada;(3)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(4)Imelda General Hospital, Department of Gastroenterology- Imelda GI Clinical Research Center, Bonheiden, Belgium;(5)Mayo Clinic Florida, Division of Gastroenterology and Hepatology, Jacksonville- FL, United States;(6)Leuven University Hospital- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(7)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Tokyo, Japan;(8)University of Cambridge, Cambridge Institute of Therapeutic Immunology and Infectious Disease- Jeffrey Cheah Biomedical Centre, Cambridge, United Kingdom;(9)The Children@E@s Memorial Health Institute, Department of Gastroenterology- Hepatology- Feeding Disorders and Pediatrics, Warsaw, Poland;(10)Université de Bordeaux, CHU de Bordeaux- Hôpital Haut-Lévêque- Service d@E@Hépato-gastroentérologie and Oncologie Digestive, Bordeaux, France;(11)Medical University of Vienna, Division Gastroenterology and Hepatology- Department of Internal Medicine III, Vienna, Austria;(12)Charité - Universitätsmedizin Berlin, Department of Gastroenterology- Infectious Diseases and Rheumatology, Berlin, Germany;(13)Eli Lilly and Company, Immunology, Indianapolis- IN, United States;(14)Eli Lilly and Company, Immunology, Indianapolis, United States;(15)Vita-Salute San Raffaele University, Gastroenterology and Gastrointestinal Endoscopy Unit, Milan, Italy;(16)San Raffaele Hospital, na, Milan, Italy;VIVID Study Group
OP36: Risankizumab Versus Ustekinumab for the Achievement of Clinical Outcomes and Symptom Improvement in Patients With Moderate To Severe Crohn’s Disease: Results From the Phase 3b SEQUENCE TrialECCO'24Year: 2024
Authors: Dubinsky, M.C.(1)*;D’Haens, G.(2);Atreya, R.(3);Abraham, B.(4);Armuzzi, A.(5);Arguelles-Arias , F.(6);Lindsay, J.O.(7);Patel, K.(8);Neimark, E.(9);Huang, X.(10);Anschutz, T.(9);van Haaren, S.(11);O’Brien , D.(11);Ferrante, M.(12);
(1)Icahn School of Medicine at Mount Sinai, Susan and Leonard Feinstein IBD Center, New York, United States;(2)Amsterdam University Medical Center- Location AMC, Department of Gastroenterology and Hepatology-, Amsterdam, The Netherlands;(3)Friedrich-Alexander-Universität Erlangen-Nürnberg, Department of Medicine 1, Erlangen, Germany;(4)Houston Methodist Hospital., Fondren Inflammatory Bowel Disease Program at the Underwood Center for Digestive Disorders, Houston, United States;(5)IRCCS Humanitas Research Hospital- Rozzano, IBD Unit, Milan, Italy;(6)Hospital Universitario Virgen Macarena, University of Seville- Gastroenterology Department, Sevilla, Spain;(7)Queen Mary University of London, Centre for Immunobiology- Barts and The London School of Medicine and Dentistry, London, United Kingdom;(8)St George@E@s University Hospitals NHS Foundation Trust-, Department of Gastroenterology, London, United Kingdom;(9)AbbVie, Clinical Development, North Chicago, United States;(10)AbbVie, Statistics, North Chicago, United States;(11)AbbVie, Medical Affairs, North Chicago, United States;(12)KU Leuven, Department of Gastroenterology and Hepatology- University Hospitals Leuven, Leuven, Belgium;
OP37: Effect of the HLA-DQA1*05 allele on the efficacy of ustekinumab in patients with Crohn@E@s Disease. Multicenter study based on the ENEIDA registry of GETECCU.ECCO'24Year: 2024
Authors: Guardiola Capón, J.(1)*;Iborra, M.(2);Padró, A.(3);de la Peña, L.(1);Serra, K.(1);Martin-Arranz, M.D.(4);Domènech, E.(5);Fernandez, A.(6);Mesonero, F.(7);Gonzalez-Muñoza, C.(8);Ferreiro-Iglesias, R.(9);Navarro, P.(10);Martín-Cardona, A.(11);Sicilia, B.(12);Sierra-Ausin, M.(13);Calvet, X.(14);Marquez, L.(15);de Francisco, R.(16);Cañete, F.(5);Gutierrez, A.(17);García-López, S.(18);Rivero, M.(19);Hinojosa, J.(20);Iglesias-Flores, E.(21);Nos, P.(2);Riestra, S.(16);Bosca-Watts, M.(10);Zabana, Y.(11);Castro, B.(22);Barreiro, M.(23);Garcia-Planella, E.(8);Ricart, E.(6);De Francisco, R.(24);Suris, G.(1);Ruiz-Cerulla, A.(1);Rodriguez-Alonso, L.(1);Orobitg, J.(1);Rodríguez-Moranta, F.(1);
(1)Hospital Universitari de Bellvitge, Gastroenterology, Barcelona, Spain;(2)Hospital Universitari i Politecnic La Fe, Gastroenterology, Valencia, Spain;(3)Hospital Universitari de Bellvitge, Genetica Molecular Laboratori Clínic, Barcelona, Spain;(4)Hospital Universitario La Paz, Gastroenterology, Madrid, Spain;(5)Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain;(6)Hospital Clínic de Barcelona, Gastroenterology, Barcelona, Spain;(7)Hospital Ramon y Cajal, Gastroenterology, Madrid, Spain;(8)Hospital Sant Pau, Gastroenterology, Barcelona, Spain;(9)Hospital Clinico Universitario de Santiago, Gastroenterology, Santiago de Compostela, Spain;(10)Hospital Clínico Universitario de Valencia, Gastroenterology, Valencia, Spain;(11)Hospital Universitari Mutua de Terrassa, Gastroenterology, Terrassa, Spain;(12)Hospital Universitario de Burgos, Gastroenterology, Burgos, Spain;(13)Complejo Asistencial Universitario de León, Gastroenterology, Leon, Spain;(14)Corporació Sanitaria Parc Taulí, Gastroenterology, Sabadell, Spain;(15)Hospital Parc de Salut Mar, Gastroenterology, Barcelona, Spain;(16)Hospital Universitario Central de Asturias, Gastroenterology, Oviedo, Spain;(17)Hospital General Universitario de Alicante, Gastroenterology, Alicante, Spain;(18)Hospital Miguel Servet, Gastroenterology, Zaragoza, Spain;(19)Hospital Universitario Marqués de Valdecilla, Gastroenterology, Santander, Spain;(20)Hospital de Manises, Gastroenterology, Valencia, Spain;(21)Hospital Reina Sofía, Gastroenterology, Cordoba, Spain;(22)Hospital Marques de Valdecilla, Gastroenterology, Santander, Spain;(23)Hospital Clinico Univeritario de Santiago, Gastroenterology, Santiago de Compostela, Spain;(24)Hospital Central de Oviedo, Gastroenterology, Oviedo, Spain;
OP38: Should all patients with newly diagnosed inflammatory bowel diseases be screened for metabolic bone disease? Results from a Danish population-based inception cohort studyECCO'24Year: 2024
Authors: Attauabi, M.(1,2,3)*;Roager Madsen, G.(2,3);Bendtsen, F.(2,3);Seidelin, J.(1);Burisch, J.(2,3);
(1)Copenhagen University Hospital - Herlev and Gentofte, Department of Gastroenterology and Hepatology, Herlev, Denmark;(2)Hvidovre Hospital, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents- and Adults, Hvidovre, Denmark;(3)Copenhagen University Hospital - Amager and Hvidovre, Gastrounit- Medical Section, Hvidovre, Denmark;
